Markets:

Overview

News

Currencies

International

Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ:ATRA)

4.405 -1.475 (-25.09%)

Streaming Delayed Price Updated: 3:38 PM EST, Jan 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Atara Bio Unveils Pivotal Data On T Cell Therapy Tabelecleucel In Transplant Patients ↗

December 14, 2021

Atara Biotherapeutics Inc (NASDAQ: ATRA) posted efficacy and safety results from its Phase 3 ALLELE study of tabelecleucel (tab-cel) for Epstein-Barr virus-positive...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

December 14, 2021

Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

20 Stocks Moving in Tuesday's Pre-Market Session ↗

December 14, 2021

Gainers MIND Technology, Inc. (NASDAQ: MIND) rose 37.2% to $1.88 in pre-market trading after the company reported it entered into a Cooperative Research and Development Agreement...

Via Benzinga

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

December 13, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021

December 09, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗

December 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...

Via Benzinga

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

November 30, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences

November 08, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 05, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

How Bad Are Atara Biotherapeutics's Earnings? | Return On Capital Employed ↗

November 05, 2021

Atara Biotherapeutics (NASDAQ:ATRA) brought in sales totaling $5.37 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 0.96%, resulting in a...

Via Benzinga

Atara Biotherapeutics, inc (ATRA) Q3 2021 Earnings Call Transcript ↗

November 04, 2021

ATRA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data

November 04, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress

November 04, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021

October 28, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

50 Biggest Movers From Yesterday ↗

October 14, 2021

Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...

Via Benzinga

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗

October 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...

Via Benzinga

Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from the Open Label Extension of ATA188 for Progressive Multiple Sclerosis at ECTRIMS 2021

October 13, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗

October 10, 2021

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive stocks and into risky bets...

Via Talk Markets

The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗

October 10, 2021

Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive...

Via Benzinga

Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-cel®)

October 04, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 01, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021

September 29, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of tab-cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (PTLD)

September 27, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

September 03, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics to Participate in a Panel Discussion at the Citi 16th Annual BioPharma Virtual Conference

September 02, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics, inc (ATRA) Q2 2021 Earnings Call Transcript ↗

August 09, 2021

ATRA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress

August 09, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

August 09, 2021

From Atara Biotherapeutics, Inc.

Via Business Wire

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.